Lung Cancer Edition: Top Headlines for Week of May 8, 2023

In this edition, tumor mutational burden linked to immunotherapy response; toripalimab regimen extends EFS in stage III NSCLC; phase 3 study designed for increasing trial diversity, and more.

Read the full coverage here:

Tumor mutational burden may be linked to immunotherapy response in advanced cancers

Perioperative toripalimab regimen extends EFS in resectable stage III NSCLC

Phase 3 study of lung cancer regimen designed to be a model for increasing trial diversity

Smoking cessation before lung cancer diagnosis significantly reduces excess mortality risk

Pembrolizumab active in diffuse malignant peritoneal mesothelioma

References:

Aggarwal C, et al. JAMA Netw Open. 2023;doi:10.1001/jamanetworkopen.2023.11181.

Lu S, et al. Abstract 425126. Presented at: ASCO Plenary Series: April 2023 Session; April 20, 2023.

Marmarelis ME, et al. JAMA Netw Open. 2023;doi:10.1001/jamanetworkopen.2023.2526.

Pragmatica-Lung Study, a streamlined model for future cancer clinical trials, begins enrolling patients (NCI press release). Published April 12, 2023. Accessed April 12, 2023.

Wang X, et al. JAMA Netw Open. 2023;doi:10.1001/jamanetworkopen.2023.11966.